The Gap
Four cancers have USPSTF-recommended screening in the United States: breast, cervical, colorectal, and lung. Everything else gets diagnosed when symptoms appear. An analysis published in Cancer Biomarkers found that 60.1 percent of American cancer deaths come from cancers with no recommended screening. That is roughly 376,000 people a year dying of diseases no one was looking for. Pancreatic cancer, the third leading cause of cancer death in the country, will kill an estimated 52,740 Americans this year. There is no approved way to look for it before symptoms appear.
The Test
On Monday, the FDA posted its staff review of GRAIL's Galleri test ahead of a September 23 advisory committee vote. The staff wrote that Galleri substantially increased cancer detection and met all prespecified success criteria for specificity, episode sensitivity, and cancer signal of origin prediction accuracy. Galleri is a prescription blood test that detects cancer-associated methylation patterns in cell-free DNA. Cancer cells shed fragments of their genome into the bloodstream. Those fragments carry methylation signatures at specific DNA sites that differ systematically from healthy-cell DNA. GRAIL's classifier scans hundreds of thousands of these methylation sites and, when it detects a cancer-consistent pattern, predicts the tissue of origin with 93.4 percent accuracy across 18 possible locations. One blood draw. Results in about two weeks. The current out-of-pocket cost is roughly $950.
GRAIL stock surged 33.68 percent to $107.97 on Monday, above every analyst price target on Wall Street. Volume hit 3.52 million shares, more than four times the 20-day average.
The Evidence
Two studies anchor the FDA submission. PATHFINDER 2 enrolled more than 35,000 adults aged 50 and older in the United States, with one-year follow-up data from 25,490 participants. Episode sensitivity was 39.3 percent across all cancers. For the 12 cancer types responsible for two-thirds of U.S. cancer deaths, sensitivity reached 69.8 percent. Specificity was 99.6 percent. Positive predictive value was 60.3 percent: roughly three in five positive results were confirmed as cancer.
The NHS-Galleri trial randomized more than 142,000 asymptomatic adults in England, aged 50 to 77, across three screening rounds over two years. Adding Galleri to standard care produced a fourfold increase in cancer detection and a sevenfold increase when combined with existing screening for breast, cervical, colorectal, and lung cancers. In the second and third rounds, stage IV diagnoses of the 12 deadliest cancers dropped by more than 20 percent. The 12 include pancreas, ovary, liver, bile duct, stomach, esophagus, lung, colorectal, bladder, head and neck, lymphoma, and myeloma.
The trial did not meet its primary endpoint. Combined stage III and IV cancer incidence showed no statistically significant reduction in the Galleri arm versus standard care alone.
The Precedent
Wednesday's vote is the first time a multi-cancer early detection test has reached an FDA advisory committee. No trial has demonstrated that Galleri reduces cancer mortality. The NHS-Galleri trial's mortality endpoint will not be reported for years. Overall sensitivity of 39.3 percent means the test misses a majority of cancers diagnosed within 12 months of the blood draw. The FDA staff noted a favorable safety profile with no device-related adverse events, modest and transient effects on anxiety, and no adverse impact on adherence to guideline-recommended screening. But the staff asked the panel to assess variation between the two studies: sensitivity differed by 3.4 percentage points and positive predictive value by 10.8 points.
The question before the panel is whether detection without proof of survival benefit justifies approval. Galleri finds cancers the current system misses. Whether finding them earlier saves lives remains unproven. The panel's recommendation will set the regulatory framework for every company behind GRAIL in this space.
The Market
GRAIL reported Q2 2026 revenue of $44.7 million, up 26 percent year over year. Test volume grew 42 percent in the first half, with more than 117,000 Galleri tests completed. The company lost $110.2 million in the quarter on a cash position of $861.6 million. Its lab can process more than one million tests annually against a current annualized pace of roughly 240,000.
The Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act, signed February 3, 2026, authorizes Medicare coverage for FDA-approved MCED tests beginning in 2028. At an estimated CMS reimbursement rate of $500 per test, GRAIL projects 50 to 60 percent gross margins at scale. The multi-cancer early detection market is valued at roughly $2 billion in 2026. Projections put it at $32.75 billion by 2035.
Exact Sciences launched Cancerguard, a multi-biomarker MCED test, in September 2025. Guardant Health expanded its Shield test to Hong Kong, Singapore, and the Philippines in March 2026 through a partnership with Manulife. The top five companies in the space hold 65 percent of the global market. But GRAIL is the first to the FDA advisory committee. If the panel recommends approval, the precedent governs the entire category. If it demands mortality evidence first, every competitor waits.
GRAL closed Monday at $107.97, valuing the company at $4.82 billion or 27.0 times annualized Q2 revenue. Every analyst target sat below the closing price: UBS at $105, RBC at $84, Baird at $70, Mizuho at $65. The stock already answered the question the FDA has not yet asked. Whether catching 70 percent of the deadliest cancers that no one currently screens for is worth the 61 percent it misses.